Posted by Michael Wonder on 21 Jul 2023
HUTCHMED receives breakthrough therapy designation in China for fruquintinib combination with sintilimab for treatment of advanced endometrial cancer
19 July 2023 - HUTCHMED today announces that the Center for Drug Evaluation of China’s NMPA has granted breakthrough therapy designation to the combination of fruquintinib and sintilimab for the treatment of patients with advanced endometrial cancer with pMMR1 tumours that have failed at least one line of platinum-based therapy.
A study for potential registration of this combination in patients with previously treated advanced endometrial cancer in China has recently completed enrolment.
